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Abstract
Inhibition of HbS polymerization is a major target for therapeutic approaches in sickle cell anemia. Toward this goal, initial efforts at
pharmacological elevation of fetal hemoglobin (HbF) has shown therapeutic efficacy. In order to identify well-tolerated, novel agents that
induce HbF in patients, we developed a high-throughput screening approach based on induction of g-globin gene expression in erythroid
cells. We measured g-globin transcription in K562 cells transfected with either g promoter elements fused with the locus control region
hypersensitivity site 2 and luciferase reporter gene (HS2g) or a b-yeast artificial chromosome in which the luciferase reporter gene was
recombined into the g-globin coding sequences (gYAC). Corresponding pharmacological increases in HbF protein were confirmed in both
K562 cells and in human primary erythroid progenitor cells. Approximately 186,000 defined chemicals and fungal extracts were evaluated
for their ability to increase g gene transcription in either HS2g or gYAC models. Eleven distinct classes of compounds were identified, the
majority of which were active within 24–48 hr. The short chain hydroxamate-containing class generally exhibited delayed maximal
activity, which continued to increase transcription up to 120 hr. The cyclic tetrapeptide OSI-2040 and the hydroxamates were shown to
have histone deacetylase inhibitory activity. In primary hematopoietic progenitor cell cultures, OSI-2040 increased HbF by 4.5-fold at a
concentration of only 40 nM, comparable to the effects of hydroxyurea at 100 mM. This screening methodology successfully identifies
active compounds for further mechanistic and preclinical evaluation as potential therapeutic agents for sickle cell anemia.
# 2003 Elsevier Inc. All rights reserved.
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1. Introduction
Through large-scale robotic screening we have sought to
identify and characterize, at the molecular level, chemical
compounds which increase expression of fetal g-globin.
HbF augmenting agents are useful in the management of
sickle cell anemia and b-thalassemias to compensate for
defects in the b-chain of adult hemoglobin (HbA). Sickle
cell disease results from a change at codon 6 of the adult b-
globin gene so that a glutamate is replace by a valine (HbA
to HbS) and afflicts 1 in 400 Afro-Americans. The altered
b-globin protein aggregates to produce an irreversible
deformation of red blood cell morphology and a vaso-
occulsive disease with severe morbidity [1]. b-Thalasse-
mias arise from a wide variety of genetic mutations which
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result in either the loss or reduced expression of the b-
globin gene. Thalassemia major, also known as Cooley’s
anemia, is characterized by marked anemia, severe hemo-
lysis, and ineffective erythropoiesis. Worldwide 240 mil-
lion people are heterozygous for these hemoglobinopathies
and these disorders are being actively selected for by vivax
and falciparum malaria [2].
The human b-like globin genes (e, g, d, b) and the
sequence designated as the locus control region (LCR)
are clustered on 100 kb of chromosome 11 (Fig. 1).
During embryonic and fetal development, globin genes
are expressed in a temporal and tissue-specific fashion,
which requires switches in both a- and b-like globin
expression so that sequential appearance of embryonic
(z2e2, a2e2, and z2g2), then fetal (a2g2), and then finally the
adult forms (a2b2 and a2d2) of hemoglobin occur [3,4].
Developmental regulation of the b-globin gene cluster is
mediated by several mechanisms. Sequences (enhancers
and silencers) both within and immediately flanking the
genes themselves confer tissue and temporal specificity
[5–8]. A 20 kb region 50 of the b-globin locus, termed the
LCR, is defined by five major DNase I hypersensitive sites
(HS-I to HS-V) and has been shown to be critical for high
level, tissue-specific globin gene expression [9–11]. The
individual genes of the b-globin locus compete for phy-
sical association with the LCR, most likely through the
interaction of transcription factors which bind the LCR
and the individual globin promoters [12,13].
In man, there is compelling evidence, genetic and
pharmaceutical, that increasing expression of g-globin
has clinical benefit in both sickle cell anemia and b-
thalassemia [14,15]. In normal individuals, between 1
and 3% of mature red blood cells express fetal g-globin.
In contrast, adults with an asymptomatic condition termed
HPFH, exhibit high levels of fetal g-globin. Based on such
clinical studies, it has been calculated that an induction of
g-globin gene expression to approximately 10–20% (or a
3- to 5-fold increase from individual baseline) of the adult
b-globin level will significantly ameliorate the symptoms
of sickle cell disease [16]. While the cis-acting DNA
elements required for g-globin transcription and HPFH
have been well defined [17–24], the identity of factor(s)
which compete for these DNA elements and signaling
pathways being modulated under physiological condi-
tions of low and high HbF synthesis, remain unclear.
Competition of linked g and b genes appears to be
mediated by multiple elements within the human g-globin
promoter [17] and likely requires recruitment of repressor
factors [25] which in turn recruit histone deacetylases
(HDAs).
Several pharmacological approaches seeking to up-reg-
ulate HbF have been developed. These include the DNA
methyltransferase inhibitor 50-aza-cytidine [26,27], the
ribonucleotide reductase inhibitor hydroxyurea [28], short
chain fatty acids, such as butyric acid [29], and a number of
other cytostatic agents. The effective concentration of
these agents can be variable from individual to individual
and these agents can show steep dose–response profiles
with relatively narrow margins of safety. As a result, we
sought to identify new agents which augment HbF, to better
define mechanisms by which pharmacological increases in
HbF may be afforded and asked the question whether
compound cytotoxicity was a requirement for induction
of g-globin transcription. Cell-based g-globin transcription
assays combined with high-throughput screening (HTS)
were used to evaluate >186,000 compounds and fungal
Fig. 1. (A) K562/HS2g luciferase screening construct. LCR hypersensitive
site 2 (HS2) was linked to the g-globin proximal promoter and inserted 50
to a luciferase reporter gene from P. pyralis. TK-neo was added and the
resulting plasmid DNA was linearized and stably integrated in K562 cells
by electroporation. (B) K562/gYAC luciferase screening construct. A
luciferase reporter gene was recombined into the Ag-globin gene within a
540 kb yeast artificial chromosome (YAC; Groveld et al., 1996).
Recombination was performed such that the ATG of luciferase displaced
the ATG of Ag. The resulting luciferase-‘tagged’ g-globin gene was stably
integrated in K562 cells by spheroplast fusion.
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extracts. Structurally distinct classes of compounds were
identified which induce g-globin transcription and HbF
accumulation, through diverse mechanisms of action. The
data support models where chromatin remodeling and/or
delayed erythroid cell cycling can lead to increased HbF
expression through both transcriptional and post-transcrip-
tional mechanisms.
2. Materials and methods
2.1. Identification of g-globin-inducing compounds
and extracts
The HS2 enhancer element of the LCR and proximal
promoter sequences from the g-globin gene [30] were
fused to the luciferase ‘reporter’ gene from H. pyralis
[31]. The TK-neo gene, present in cis on the reporter
plasmid, was used as the selectable marker for mammalian
cell transfection. Human K562 cells, which display early
erythroid and myeloid progenitor markers, were stably
electroporated to express HS2g luciferase. Luciferase-
‘tagged’ g-globin yeast artificial chromosome (YAC;
gYAC) was constructed as previously described [32] where
the luciferase gene was recombined into YAC DNA 30 of
the Ag promoter within the context of the full b-globin
locus. gYAC DNA was introduced into K562 cells and
MEL cells by protoplast fusion and cells selected for
puromycin resistance. Individual clonal lines were evalu-
ated by (i) basal luciferase expression; (ii) faithful integra-
tion of linear DNA as determined by Southern
hybridization; and (iii) inducible regulation of the inte-
grated reporter construct by hemin and 5-aza-cytidine (4-
to 6-fold for HS2g and >3-fold for gYAC). Expression
levels from multiple K562 lines expressing HS2g or gYAC
genes were suitable for HTS, while expression levels of
gYAC in MEL-derived clones were insufficient.
Chemical compounds were synthesized as discrete com-
pounds, dissolved in neat DMSO and were screened on an
individual basis at a concentration of 12 mM. Fungal
extracts were prepared by freeze drying the fermentation
material, broth and mycelia together, followed by extrac-
tion with methanol. Extracts were dried and subjected to
solvent fractionation to provide three crude fractions
(water–methanol, chloroform, and hexane) which were
tested for biological activity at a 1:4 dilution of the starting
culture volume (N/4). Active fractions were further pur-
ified by reverse-phase HPLC. Full characterization of
selected compounds was achieved using mass spectro-
metry and NMR techniques.
K562/HS2g and K562/gYAC cells were plated at
10,000 cells per well in phenol red-free RPMI-1640 media,
2% fetal calf serum (FCS; Hyclone), 20 mM L-glutamine,
penicillin (100 units/mL), streptomycin (100 mg/mL),
20 mM HEPES, pH 7.4, in 96-well microtiter plates. Cells
were induced with compound (12 mM) or fungal extract
(N/4) for a period of 24 hr. The final compound solvent
concentration was 0.2% DMSO, which was used as the
negative control. The positive control was 1 mM aza-cyti-
dine. Upon completion of induction period, luciferase
buffer was added to each well to achieve a final concen-
tration of 100 mM Tris–acetate, pH 7.9, 20 mM magne-
sium acetate, 2 mM EGTA, 1% Brij 58, 100 mM 2-
mercaptoethanol, 36 mM ATP, 150 mM luciferin. Cells
were allowed to lyse for 5 min at room temperature after
which the chemiluminescent signal was measured (Dyna-
tech Lab ML1000-medium gain setting). A preliminary
screen of approximately 5000 compounds was performed,
incorporating internal controls on each microtiter plate.
These studies defined criteria to accept or reject HTS data,
requiring that: (1) penicillic acid or 5-aza-cytidine induced
HS2g reporter gene expression >4-fold or gYAC expres-
sion >2-fold; (2) that the baseline signal was >0.05 lumin-
ometer units; and (3) that the coefficient of variation of
controls on each microtiter plate was <20%.
2.2. Cytotoxicity assays
MTT (3-[4,5 dimethylthiazol-2-yl-]-2,5-diphenyl tetra-
zolium bromide), a commonly used colorimetric substrate,
was used to measure mitochondrial respiration in order to
assess cell viability. Cells were plated as described for the
luciferase reporter gene assays. After incubation with test
compounds for 24 and 48 hr, 20 mL of 3 mg/mL MTT was
added and cells incubated for 2 hr at 378, 5% CO2. One
hundred microliters of 10% SDS was added to all wells for
4 hr at 378 to allow for lysis and solubilization of MTT.
Mitochondrial conversion of MTT was assessed by mea-
surement of light absorbance at 540 nM. Background
(from the PBS control) was subtracted and the data
expressed as % inhibition of cell growth.
2.3. HbF ELISA of K562 hypotonic lysates
K562 cells were exposed in duplicate to compound for a
period of 4 days. Cells were collected by centrifugation
(1000 g; 5 min), media aspirated, cells washed with PBS,
and the cell pellet lysed in ice-cold H2O by vortexing for
40 s. Nuclei were removed by centrifugation (13,000 g;
48 for 4 min). Cleared lysate was removed, protein con-
centration determined, and extracts stored at 708.
Horseradish peroxidase (HRP)-conjugated monoclonal
antibody to HbF (Isolabs/Wallace) was used for ELISA
determination of HbF concentration. Anti-HbF is approxi-
mately 100 times more reactive to HbF than HbA. Standard
curves were generated using HbF standard (10% HbF,
90% HbA) serially diluted 1:2 in 25 mg/mL BSA from 1 to
0.015 mg/mL HbF. 25 mg/mL BSA served as the assay
background control. Hypotonic lysates were diluted to
25 mg/mL. Protein samples were added in triplicate to
Immulon-4 microtiter plates for colorimetric detection
or Microlite II microtiter plates for chemiluminescent
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detection (Dynex Technologies), using an excess of 0.1 M
Na2HCO3, pH 9.0, at room temperature for 2 hr. Plates
were washed four times with 50 mM Tris, pH 8.0, 150 mM
NaCl, and 0.05% Tween-20 (TST). Anti-HbF was diluted
1:1000 to 1:2000 in TST containing 1% BSA (Fraction V)
and 100 mL was added to each well, incubated for 2 hr at
room temperature, washed four times with TST, and HRP
substrate added. For colorimetric detection, 100 mL of
TMB substrate (Kirkegaard & Perry Laboratories) was
added and incubated for 30 min, quenched by the addition
of 20 mL 4 N H2SO4, and read at 450 nm/630 nm. For
chemiluminescent detection, 100 mL of complete LBA
(Pierce Chemical Co) was added per well and measured
2 hr post-substrate addition. Correlation coefficients of
standard curves were 0.95–1.0 and not accepted if below
0.9.
2.4. Human primary blood progenitor culture
A two phase liquid culture system was used [33] with
modification. Human blood partially enriched for mono-
nuclear cells (buffy coat) was diluted 1:1 with sterile PBS
laid over 1.077 g/mL Ficoll (Invitrogen Corporation) and
centrifuged at 300 g. Mononuclear cells at the Ficoll–
aqueous interface were removed, diluted with PBS, col-
lected by centrifugation (300 g), and washed twice with
PBS. Mononuclear cells containing erythroid progenitors
from 2 units of blood were cultured in 80 mL ‘Phase I’
medium comprising: a-modified Eagle’s media (aMEM;
Invitrogen Corporation), 10% FCS (Stem Cell Technolo-
gies), 20 mM L-glutamine, penicillin (100 units/mL), strep-
tomycin (100 mg/mL), human cytokines (R&D Systems
Inc.) 10 ng/mL IL-3, 10 ng/mL IL-6, 10 ng/mL granulocyte
colony stimulating factor (G-CSF), 10 ng/mL granulocyte-
macrophage colony stimulating factor (GM-CSF), 20 ng/
mL SCF, and 1 mg/mL cyclosporin A (Cayman Chemical
Corp.). Phase I culture was expanded for 5–7 days, collected
by centrifugation, washed twice in aMEM, and transferred
to ‘Phase II’ medium comprising: aMEM, 10–30% FCS,
20 mM L-glutamine, penicillin (100 units/mL), streptomy-
cin (100 mg/mL), 1 unit/mL erythropoietin (EPO), 10 ng/
mL SCF, 1 mM dexamethasone, 10 mM b-mercaptoethanol.
The effect of compound on HbF in primary cultures was
assessed by exposing cells plated in Phase II media at
3 106 cells/mL, 5% CO2, 378, in a humidified incubator,
to a range of compound concentrations for 4 days (corre-
sponding to days 4–8 in Phase II).
2.5. K562 extract preparation and protein blotting
To measure histone acetylation, K562 cells (1
107 cells) were exposed to compounds for 24 hr. Cells
were pelleted by centrifugation (500 g; 5 min), washed
once with PBS followed by resuspension in 10 mM
HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, and 1.5 mM PMSF. HCl was added to 0.2 M for
30 min at 48. The extract was subjected to centrifugation at
11,000 g, for 10 min at 48. The supernatant fraction was
dialyzed against 0.1 M acetic acid (once for 1 hr), followed
by dialysis against water (three times). Cell extracts were
subjected to SDS–PAGE, transferred to nitrocellulose
membrane, and incubated with anti-acetyl histone anti-
body (Upstate Biotechnology) for 2 hr at room tempera-
ture. Primary antibody incubation was followed by
incubation with the appropriate HRP-conjugated second-
ary antibody for 1 hr at room temperature and chemilu-
minescent detection (ECL; Amersham Bioscience).
2.6. Stress gene profiling
HepG2 cells were stably transfected with individual
reporter gene constructs employing the luciferase gene
under the control of the stress-responsive promoters for
c-jun, growth arrest and DNA damage 153 (GADD153),
glutathione-S-transferase Ya (GST Ya), heme mono-oxy-
genase (HMO), heat shock protein 70 (HSP70), or the
hypoxia inducible factor 1 (HIF-1 RE), nuclear factor AT
(NF-AT RE), nuclear factor kappa-B (NF-kB RE), or
xenobiotic (XRE) response elements. Stably transfected
clonal cell lines were isolated and selected for appropriate
response to two or more known modulators of the parti-
cular promoter element. Assay conditions for each cell line
were optimized for exposure time, serum concentration,
and cell number.
Cells were plated onto white 96-well microtiter plates
precoated with collagen at either 10,000 (GADD153, HIF-
1 RE) or 20,000 cells per well (c-jun, GST Ya, HSP70,
HMO, NF-AT RE, NF-kB RE, XRE) in 150 mL DMEM
supplemented with L-glutamine, non-essential amino
acids, and either 1% (GADD153, GST Ya, HIF-1 RE,
HMO, NF-AT RE, NF-kB RE, XRE) or 10% (c-jun,
HSP70) FCS. After 24 hr incubation (378, 5% CO2) the
cells were transferred to a fully robotic liquid and plate
handling station where compounds were added in triplicate
at six concentrations in a 5-fold dilution range. The plates
were further incubated for either 6 hr (HMO), 8 hr (c-jun,
GADD153, GST Ya, NF-AT RE, NF-kB RE), 16 hr
(HSP70, XRE), or 24 hr (GST Ya, assayed at two different
time points), and luciferase assays performed.
3. Results
3.1. Identification of compounds which increase g-globin
transcription in K562 and primary progenitor cells
Our initial goal was to identify novel agents which
induce g-globin transcription through random HTS of
>186,000 entities and to categorize their mechanisms of
action. Two assay approaches were used: (1) a fusion of the
LCR hypersensitivity site 2 enhancer with the g proximal
promoter (HS2g) 50 to a luciferase reporter gene (Fig. 1A);
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and (2) a bYAC-based approach in which the luciferase
reporter gene was integrated by homologous recombina-
tion 30 of the g-globin promoter within the context of the
full b-globin locus (Fig. 1B; ref. [32]). Extracts and
compounds were evaluated and selected according to the
scheme shown in Fig. 2, where inductions of >4-fold for
HS2g and of >2-fold for gYAC were required for further
investigation of the test agent. Approximately 96,000
extracts from fungal, marine, seed, and herbal libraries
and 48,400 compounds from chemical libraries were
screened in the K562/gYAC assay and approximately
23,000 extracts and 31,000 compounds were screened in
the K562/HS2g assay. Extracts or compounds which
increased g-globin reporter activity greater than 4-fold
in K562/HS2g cells or 2-fold in K562/gYAC cells, as
compared with vehicle control (0.2% DMSO), were
selected for further evaluation. The frequency distribution
of the fold transcription increases from resulting incuba-
tion with chemical compound or fungal extracts are shown
in Fig. 3. The y-axis records fold induction relative to
control. Compounds or extracts are distributed along the
x-axis, which has no units. Most extracts and compounds had
little or no effect on g-globin gene expression and showed a
normal distribution centering on 1.0, or no fold induction.
The scales between panels differ due to the increased
sensitivity of HS2g over gYAC and the often larger fold
inductions observed with fungal extract mixtures relative to
single chemical compounds. The enhanced activity of fungal
extracts is most likely due to the sensitivity of the assay to
specific classes of cytotoxic compounds and to the multiplex
nature of whole fungal extracts (data not shown). The
frequencies of identifying positively scoring compounds
and natural product extracts in the automated screening
approach were 1 and 2.5%, respectively.
Active fungal culture extracts were prioritized on the
basis of efficacy, potency, and cytotoxicity at 24 and 48 hr
time points. Extracts were dereplicated on the basis of
HPLC retention time to eliminate previously identified
 
 
 
 
Fig. 2. Flow schematic illustrating natural product extract and chemical compound progression pathways.
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activities. From the 59 purified fungal metabolites, 5 potent
and efficacious activities were characterized (not shown).
These comprised a furanone (5-[1,2-dimethyl-propenyl]-
5-hydroxy-4-methoxy-5H-furan-2-one), an isoflavone
(7-hydroxy-3-[4-hydroxy-phenyl]-chromen-4-one), a sub-
stituted phenol (1-[2,4,6-trimethoxy-phenyl]-but-2-en-1-
one), a dihydropyranone (acetic acid 2-[8-methyl-9-oxa-
bicyclo[4.2.1]nona-2,4-dien-7yl]-6-oxo-3,6-dihydro-2H-
pyran-3-yl-ester), and a cyclic tetrapeptide (OSI-2040;
cyclo-[N-O-methyl-L-Trp-L-Ile-D-Pip-L-2-amino-8-oxo-
decanoyl]). Of the fungal metabolites, only OSI-2040
showed sufficient efficacy, potency, and differential
cytotoxicity to warrant further study. OSI-2040, a cyclic
tetrapeptide, was isolated from Fusaria extracts and likely is
to be produced from tryptophan, isoleucine, a pipecolic acid,
and an amino decane derivative. Three of the four residues
are uncommon amino acids and active variants of OSI-2040
in which the nitrogen methoxy group is substituted with
hydrogen also have been isolated. OSI-2040 refers to either
methoxy or hydrogen substituted entity, which display
indistinguishable bioactivity. OSI-2040 was shown to
increase both g-globin transcription [34] and HbF accumu-
lation using three distinct assays: the HbF ELISA (Table 1),
hemoglobin staining assays (benzidine colorimetric and
LBA chemiluminescent assays; data not shown), and a
hemoglobin cation-exchange HPLC assay (data not shown).
Of the chemical compounds, 62 were selected based on
potency, efficacy, and relative lack of cytotoxicity. Of
these, 35 were aniline derivatives. More than 20 of the
anilines are condensed as either amides, ureas, or carbox-
amides. Activity profiles of selected compounds from each
of the chemical classes are shown in Table 1. The anilide
OSI-168961, the amide OSI-102695, and the benzoyl OSI-
169055 showed maximal transcriptional inductions of 3.2-,
Fig. 3. Frequency distribution of fold transcription increases resulting incubation with chemical compounds or fungal extracts. The y-axis records fold
induction relative to vehicle control (0.2% DMSO). Compounds/extracts are distributed along the x-axis, which has no units. (A) HS2g cells exposed to
compounds (scale 0–10); (B) HS2g cells exposed to fungal extracts (scale 0–100); (C) gYAC cells exposed to compounds (scale 0–7); and (D) gYAC cells
exposed to fungal extracts (scale 0–17). Fold induction of 1 indicates no effect, while inductions <1 indicate cytotoxicity and/or repression. Clusters reflect
related compounds in close proximity within the chemical and fungal extract libraries. Shading in panels B and D reflect different fungal growth conditions.
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Table 1
Compound classes and activity in K562/gYAC transcription assays, K562 cytotoxicity assay (MTT), K562 HbF ELISA, and human primary progenitor HbF
ELISA
Compound
ID/structural
class
Side chains Transcription (24 hr) Cytotoxicity
(48 hr) IC50
(mM)
Maximum HbF increase (4 days)
Y X EC50 (mM) Maximum
induction
K562 cells Human
progenitor cells
OSI-2040 0.15 4.3 0.5 5.4 (0.1 mM) 4.5 (0.04 mM)
OSI-168961 1-Hydroxy 2-napthyl 2-Chloro-4-nitro 0.1 3.2 >50 2.8 (2 mM) 2.4 (0.8 mM)
OSI-168996 1-Hydroxy-4-chloro
2-napthyl
4-Cyano 1.0 3.8 30 3.8 (0.7 mM) 2.4 (0.8 mM)
OSI-97345 3-Methylbenzo[b]thiophene 4-Methyl 5.0 3.6 >50 2.0 (15 mM) 4.1 (4 mM)
OSI-168992 Cyclohexyl 2-Nitro 1.0 2.0 >20 3.1 (20 mM) 2.6 (0.8 mM)
OSI-169055 1-Benzyl-1H-
pyrrolo(1,2-A)imidazol-5-yl
<0.1 2.2 >50 2.1 (20 mM) nd
OSI-101820 4-Bromo 3-Nitro 8.0 3.3 >50 2.1 (13 mM) 4.7 (4 mM)
OSI-169170 Hydroxy 4-Methoxyphenyl 8.0 5.8 >50 3.2 (2 mM) 7.2 (20 mM)
OSI-22121 2,3-Propylene 3.5 2.6 30 5.4 (25 mM) 2.1 (0.8 mM)
OSI-169040 3(2-Keto indolyl) 9.0 2.9 >50 2.0 (20 mM) nd
OSI-102695 0.9 2.5 >20 1.7 (20 mM) 3.5 (4 mM)
OSI-169050 0.4 3.0 >50 2.3 (6 mM) 1.5 (20 mM)
Aza-cytidine 0.6 2.5 1 3.1 (1 mM) 10 (1 mM)
Hydroxyurea na 1.2 nd 2.8 (200 mM) 5.9 (100 mM)
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2.5-, and 2.2-fold, respectively, potencies in the nM EC50
range with cytotoxicity apparent at >20 mM. The carba-
mate OSI-168992, and anilides OSI-97345 and OSI-
168996, the phenylurea OSI-101820, the phenyltriazol
OSI-169170, the amino-triazine OSI-22121, and the phe-
nylhydrazone OSI-169040 exhibited maximal inductions
ranging from 2- to 5.8-fold with low mM potencies. In these
assays, OSI-2040 showed a 4.3-fold stimulation of gYAC
reporter activity after 24 hr exposure with an EC50 of
150 nM and cytotoxicity, following 48 hr exposure in
K562 cells in vitro, was apparent at concentrations
>500 nM. In comparison, aza-cytidine showed transcrip-
tional activity (gYAC) of 2.5-fold at 600 nM with cyto-
toxicity apparent at 1 mM. The reference compounds
sodium butyrate and hydroxyurea showed little or no
induction (<2-fold) of reporter expression after 24 hr
exposure, but did increase reporter expression and HbF
accumulation after longer incubation periods. For exam-
ple, both hydroxyurea (100 mM) and sodium butyrate
(1 mM) increased K562/HS2g expression by 10-fold after
96 hr exposure, while in the same experiment OSI-2040
(0.3 mM) showed a 47-fold increase. The assays for globin
protein, the HbF ELISA, and the benzidine staining assay,
generally were less sensitive. In K562 cells exposed to
compounds for 72 hr benzidine staining (measuring total
globin protein) increased 8-fold for OSI-2040 (4.8 mM),
2.5-fold for hydroxyurea (200 mM), 3-fold for hydroxyurea
(500 mM),1.5-fold for sodium butyrate (1 mM), and 2.2-
fold for sodium butyrate (5 mM). In the HbF ELISA
measurements in K562 cell exposed to compound for
96 hr, hydroxyurea (200 mM), aza-cytidine (1 mM), and
OSI-2040 (100 nM) increased HbF 2.8-, 3.1-, and 5.4-fold,
respectively, as shown in Table 1. Sodium butyrate was not
tested in the HbF ELISA. These findings were generally
true for many compounds where, at non-cytotoxic con-
centrations, EC50 values for potency increased with
increased cell exposure time.
The selected compounds showed g-globin-inducing
activity in both K562 and primary human progenitor cells
in vitro. Primary peripheral hematopoietic progenitor cells
were cultured [33] under conditions resulting in the
expansion and differentiation of erythroid cells and the
induction of g-globin (approximately days 2–4) and
b-globin (approximately days 4–8). To minimize donor
to donor variation progenitor cells from two to three
donors were pooled in Phase II culture (day 4) and HbF
concentration measured by ELISA. A relatively short
incubation period of 96 hr was used to minimize potential
in vitro. Seven independent experiments were performed
using duplicate cultures for each compound and with three
ELISA determinations for each data point. A three-way
ANOVA of the data was performed (compound vs. con-
centration vs. experiment; Table 1). Compound potencies
generally were in the low mM EC50 range, with HbF
increases of 2- to 7.2-fold over concentrations from 0.8
to 20 mM observed. The exception was OSI-2040 which
showed significant (P < 0:05) g-globin-inducing activity
of 5.4- and 4.5-fold in K562 and human progenitor cells,
respectively, at low nM concentration (100 nM for K562
cells and 40 nM for human progenitor cells). In compar-
ison, aza-cytidine at 1 mM showed inductions of 3.1- and
10-fold in K562 and human progenitor cells, respectively.
Hydroxyurea showed g-globin-inducing activity of 2.8-
and 5.9-fold in K562 and human progenitor cells, though
with low potency (>100 mM).
3.2. Directed screening for inducers of g-globin
transcription
In initial validation studies, approximately 80 com-
pounds with known activities in cellular signaling were
evaluated in the K562/gYAC assay. The compounds acet-
ohydroxamic acid (urease inhibitor), genistein, and quer-
cetin (tyrosine kinase inhibitor), 12-phorbol 13-myristate
(protein kinase C activator), ionomycin, and A23187 (cal-
cium influx), N-acetyl cysteine (antioxidant), phenamil
(sodium channel blocker), and olomucine (cyclin-depen-
dent kinase inhibitor) induced g-globin promoter–reporter
activity by >2-fold. Few of these compounds had sufficient
potency (<10 mM) or tractable chemical structures for
further evaluation. However, analogs of acetohydroxamic
acid were further investigated.
Proprionic hydroxamic acid (PHA) increased reporter
activity in K562/HS2g at concentrations >4 mM, with
maximal activity observed at 70 mM as shown in Fig. 4.
Figure 4 shows log concentration in mM on the x-axis and
fold increase in g expression on the y-axis. Increases in g
transcription were time dependent, ranging from 2.6-fold
at 48 hr to 6.7-fold at 120 hr of exposure to 100 mM PHA.
Reducing PHA concentration to 20 mM diminished g
transcription to 2.1- to 3.3-fold at 48 and 120 hr expo-
sure, respectively. Six hydroxamic acid analogs were
compared in order to assess possible structure–activity
relationships. All analogs, with the exception of com-
pound 15260, were found to increase HS2g expression
(Table 2). R-02210 showed markedly greater induction at
early time points than PHA, NS43789, or R-44534,
despite showing similar maximal inductions of 5-
to 7-fold at or around 100 mM compound concen-
tration. Both R-02761 and NS41080 were more potent,
with maximal activity observed at 20 mM. However,
NS41080 showed less time dependence to HS2g induc-
tion and showed a more pronounced leftward tail in the
dose–response curves, suggestive of a greater window
between the efficacious and cytotoxic compound con-
centrations.
3.3. HDA inhibition and activation of cellular stress
pathways
Short chain fatty acids, such as butyrate, have been
shown to induce g-globin transcription and exhibit HDA
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inhibitory activity at relatively high concentrations [35].
The potential for the g-globin-inducing compounds to
inhibit HDA activity in K562 cells was examined. Using
anti-acetyl histone antibody, increased acetylated histone
was clearly observed in cells exposed to OSI-2040 for 18 hr,
but was not detected in K562 cells treated with other
g-globin-inducing compounds (Fig. 5A). In separate experi-
ments, PHA also was shown to have HDA inhibitory activity
Fig. 4. Dose–response activity profile of K562/HS2g cells exposed to proprionic hydroxamic acid (PHA) for 48, 72, 96, or 120 hr. Log concentration is
indicated on the x-axis. Fold g-globin transcriptional increase is shown on the y-axis.
Table 2
Activity of hydroxamate-containing analogs in stimulating g-globin transcription after 96 hr exposure in KS62/HS2g cells
Compound Structure EC50 (mM) Maximal fold induction
Acetohydroxamic acid 250 2.6
Proprionic hydroxamic acid 30 4.7
R-02210 50 5.5
R-02761 4 3.0
R-44534 50 4.1
15260 – No effect
NS41080 5 4.0
NS43789 40 4.0
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in K562 cells (Fig. 5B). The OSI-2040 concentration
used was 1 mM, which provides maximal g-globin-inducing
activity yet was below the 24 hr cytotoxic IC50.
Many of the g-globin-inducing compounds initially
identified showed cytotoxicity, as measured by a reduction
in MTT conversion and by a sharp decline in reporter
signal, at concentrations at or somewhat above those
required for maximal induction of transcription. To inves-
tigate whether stress-responsive pathways form an obligate
mechanism in g-globin induction, the active compounds
OSI-97345, OSI-102695, OSI-101820, OSI-168996, OSI-
168961, OSI-169050, OSI-169170, OSI-2040, and 5-aza-
cytidine were investigated for their ability to induce the
stress-responsive promoters or response elements from
c-jun (early-immediate stress response), GADD153 (growth
arrest and DNA damage), GST Ya (Phase II metabolic
enzyme), HIF-1 RE (hypoxia response element), HSP70
(heat shock and protein damage), heme oxygenase (oxida-
tive stress), NF-kB RE (oxidative stress, DNA damage),
NF-AT (calcium signaling), and XRE (aryl hydrocarbon
(AH) receptor activation). A panel of nine stably transfected
HepG2 cells containing luciferase reporter genes linked to
individual promoters and response elements were exposed
to each of the compounds along with an appropriate positive
control for each marker, in triplicate at six doses (5-fold
serial dilutions) as described in Section 2.
Table 3 indicates stress markers which were significantly
induced by each compound (>2-fold induction, P ¼ 0:05),
the magnitude of the greatest observed induction (in fold
induction and as a percentage of the maximum observed
effect), the dose at which the highest induction was
observed and the P value obtained from a t-test of the
triplicate dose points compared to the 12 negative controls
in each case. Only treatments resulting in at least a 2-fold
(P < 0:05) increase in luciferase expression are shown.
Shown is the concentration of compound at which max-
imum induction of stress response was seen, fold increase
in luciferase activity, % of maximum observed increase,
and P value (t-test). Notably, all of the compounds, with the
exception of OSI-169170, induced transcription of the
XRE reporter construct, suggesting that these compounds
are able to bind and activate the AH receptor. OSI-97345
was the most powerful inducer of XRE, causing a 5-fold
increase in luciferase expression at a dose of 16.7 mM. OSI-
2040 was the most potent inducer of XRE, giving a 4-fold
increase at 0.12 mM. Four of the compounds, OSI-2040,
OSI-97345, OSI-102695, and OSI-169170, induced
expression from the HSP70 promoter. Increased expression
of HSP70 would suggest that exposure of cells to these
compounds results in damage to proteins or a disruption of
protein synthesis or folding [36]. Induction of HSP70
driven luciferase expression by OSI-97345, OSI-102695,
and OSI-169170 was fairly weak (2.5-fold) but OSI-2040
induced a 6.8-fold increase in expression, comparable to
that observed with the alkylating agent methane methyl
sulfonate (MMS). OSI-2040 also induced the GADD153
reporter construct which may indicate a genotoxic
potential [37], as well as the c-jun and NF-kB RE con-
structs. The level of induction of GADD153 by OSI-2040
was small (2.1-fold) compared to that observed with MMS
(15.2-fold) and the effect of OSI-2040 on the c-jun and
NF-kB RE constructs was also small. OSI-169050 and
OSI-169170 also weakly induced the GADD153 reporter
construct (2.3- and 2.1-fold, respectively). Neither OSI-
169050 nor OSI-169170 significantly induced c-jun or
NF-kB RE, although both did induce the GST Ya construct,
Fig. 5. (A) OSI-2040 treatment increases histone H4 acetylation in K562
cells. K562 cells were treated for 24 hr with maximally acting
concentration of OSI-97345 (lane 1), OSI-102695 (lane 2), OSI-22121
(lane 3), OSI-101820 (lane 4), OSI-168992 (lane 5), OSI-168996 (lane 6),
OSI-168961 (lane 7), OSI-169050 (lane 8), OSI-169170 (lane 9), OSI-
2040 (lane 10), or 0.2% DMSO (lane 11). Extracts were subjected to SDS–
PAGE, transferred to nitrocellulose, and probed with anti-acetyl histone H4
antibody (Upstate Biotechnology). Acetyl histone H4 (11 kDa) was
observed extracts from OSI-2040-treated cells, but not in extracts from
cells exposed to 0.2% DMSO or compounds OSI-97345 to OSI-169170.
Weak reactivity of the antibody to acetylated histone H2B (14 kDa) may
contribute to band broadening. (B) Proprionic hydroxamic acid (PHA)
stimulates histone H4 acetylation in K562 cells. K562 cells were treated
for 24 hr with 0.2% DMSO vehicle (lane 1), 10 mM PHA (lane 2), 100 mM
PHA (lane 3), 1 mM OSI-2040 (lane 4) histones extracted and probed with
anti-acetyl histone antibody as described for panel A. The OSI-2040
concentration of 1 mM provides maximal g-globin-inducing activity yet
was below the 24 hr cytotoxic IC50.
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as did OSI-97345 and OSI-102695. Expression of GST Ya
is induced in response to a variety of electrophilic com-
pounds and phenolic antioxidants [38].
The HIF-1 RE construct was induced by the compounds
OSI-168996, OSI-168961, and OSI-169050, suggesting
that these compounds elicit a hypoxia response in HepG2
cells. Our own previous work with this cell line 1 has shown
that the HIF-1 RE reporter construct may be activated
by compounds known to activate the AH receptor, such
as 3-methylcholanthrene (MC) and benzo(a)pyrene (MC
elicited a 3.7-fold increase in HIF-1 RE driven luciferase
expression in this study). Not all of the compounds which
induced the XRE construct also induced the HIF-1 RE
construct, however, indicating that the responses are not
completely equivalent.
4. Discussion
Chemically diverse compounds which induce g-globin
transcription through HDA inhibitory and distinct cell
stress-associated mechanisms were identified. These effects
Table 3
Maximum fold inductions of nine stress response reporter constructs by g-globin transcription-inducing and control compounds
Compound [Compound] (mM) Markers induced >2-fold (P  0.05) Fold induction % Max P
Control compounds
3-Methyl cholanthrene 20 GST Ya (8 hr) 2.7 20 0.007
20 GST Ya (24 hr) 5.0 100 0.004
7 HIF-1 RE 3.7 100 0.006
20 XRE 5.5 48 0.001
Calcium ionophore (A23187) 2 HSP70 3.3 8 0.020
20 NF-AT 11.4 100 0.001
Methane methyl sulfonate (MMS) 1000 c-jun 10.1 100 0.000
1000 GADD153 15.2 58 0.000
333 GST Ya (8 hr) 4.7 40 0.012
333 HSP70 5.9 24 0.036
333 XRE 2.1 12 0.004
12-Phorbol 13-myristate (PMA) 0.7 c-jun 8.1 78 0.000
0.2 GADD153 25.5 100 0.001
0.7 GST Ya (8 hr) 10.2 100 0.001
0.2 HMO 19.8 100 0.001
0.2 HSP70 21.7 100 0.004
0.7 NF-kB RE 1030.0 100 0.004
2 NF-AT 8.6 60 0.029
0.7 XRE 10.2 98 0.019
Test compounds
OSI-97345 17 GST Ya (8 hr) 2.5 16 0.005
17 GST Ya (24 hr) 2.8 38 0.010
6 HSP70 2.4 7 0.028
17 XRE 5.0 44 0.000
OSI-102695 4.2 GST Ya (24 hr) 2.0 18 0.043
1.4 HSP70 2.1 4 0.043
13 XRE 2.5 16 0.003
OSI-101820 14 XRE 2.9 20 0.001
OSI-168992 1.9 HIF-1 RE 2.2 48 0.000
0.6 XRE 2.8 20 0.003
OSI-168961 8 HIF-1 RE 2.4 79 0.035
3 XRE 2.3 15 0.006
OSI-169050 14 GADD153 2.3 6 0.004
42 GST Ya (8 hr) 2.3 13 0.009
125 GST Ya (24 hr) 2.5 27 0.003
42 HIF-1 RE 3.3 95 0.000
42 XRE 3.9 32 0.002
OSI-169170 42 GADD153 2.1 5 0.001
14 GST Ya (8 hr) 2.1 12 0.019
OSI-2040 10 c-jun 2.0 11 0.006
10 GADD153 2.1 4 0.000
0.4 HSP70 6.8 28 0.022
10 NF-kB RE 4.1 0 0.022
0.1 XRB 4.2 34 0.006
Proprionohydroxamic acid (PHA) <50 None – – –
1 Unpublished results.
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could be observed in both K562 cells and human primary
progenitor cells. In evaluating the screening systems
employed, the isolated K562/HS2g clones were consider-
ably more responsive to the K562/gYAC clones to com-
pounds which induce the transcription of g-globin, for
example, as observed in the frequency distribution data
shown in Fig. 3. This was true both with known com-
pounds, like aza-cytidine and hydroxyurea, and the novel
compounds identified here. Both K562/HS2g and K562/
gYAC reporter cell lines identified compounds capable of
increasing g-globin expression both in the reporter assays
as well as in human primary progenitor cells (Table 1).
The majority of the compounds which activated g-globin
transcription shared a common motif of two aryl moieties
separated by less than 4 A˚ using one, two, and three bond
linkers of several types (urea, carbamate, amide, carbonyl,
ether, thiourea, etc.). The phenyl imidazoles, phenylhy-
drazones, and phenyltriazols also may fall into this general
structural class. Whether these compounds interact with
the same cellular targets as the related, less potent com-
pound, hydroxyurea, or have distinct protein targets
remains to be determined. The most potent and efficacious
activity was observed with the HDA inhibitor OSI-2040,
which markedly increased HbF both in established and
primary erythroid cell cultures at low nM concentration.
The HDA inhibitory activity of OSI-2040 (termed apicidin
by Merck) has been reported by other investigators [39–41]
and found to be more effective than trichostatin A and MS-
275 in stimulating histone hyperacetylation in K562 cells
[39]. PHA also was shown to inhibit HDA, though with
much lower potency and with slower kinetics of both HDA
inhibition and g-globin induction. Both aceto- and pro-
prionic hydroxamic acids have been clinically investigated
as urease inhibitors and showed good aqueous solubility.
The hydroxamates generally showed relatively poor
potency (>20 mM) but exhibited substantial efficacy after
long-term exposure (96 hr) as shown for PHA in Fig. 4.
One central question we investigated here was whether
compounds which induce g-globin could be non-toxic at
efficacious concentrations in vitro. The data obtained from
screening of >186,000 compounds and extracts suggest
that for the vast majority of compounds tested some degree
of cytotoxicity is required for g-globin induction. One of
the better tolerated cytotoxic chemotherapy agents which
can increase HbF is hydroxyurea, sometimes used clini-
cally in combination with EPO [28]. It has been proposed
that hydroxyurea acts to stimulate the synthesis of early
erythroid progenitors capable of g-globin transcription,
presumably through preferential ablation of a more mature
cell compartment leading to progenitor cell expansion.
Recent data have shown hydroxyurea can activate p38
MAP kinase in a sustained fashion and attenuated extra-
cellular signal-related kinase (ERK) and the c-jun N-
terminal kinase (JNK). Further, inhibition of p38 reduced
the ability of hydroxyurea to stimulate globin production in
K562 cells [42], strengthening a role for p38 activation in
hydroxyurea action. In the case of the biaryl substituted
ureas, amides, and carbamates, the common mechanistic
response was the activation of the aryl hydrocarbon
response pathway (XRE) and not the activation of c-jun.
The mechanisms of these compounds were distinct from
those of OSI-2040 which has potent HDA inhibitory
activity and a distinct gene expression pattern as measured
by microarray hybridization and by RT–PCR.2 Alterations
in cell cycling have been inversely correlated with tran-
scription of g-globin [43]. One frequently used measure of
cell cycling is the phosphorylation status of the retino-
blastoma protein (Rb), which is phosphorylated in the G1
to S transition. In T47D cells, many of the g-globin-
inducing compounds identified here cause the hypopho-
sphorylation of Rb, indicative of cell cycle arrest or delay
(data not shown). Conversely, in preliminary experiments
the cdk inhibitors, roscovitine and olomucine, increased
the expression of the g-globin reporter line K562/HS2g
(data not shown), though their inductions were modest
compared to the HDA inhibitor OSI-2040. These data
support the hypothesis that the biaryl ureas, amides, and
carbamates, act in part through cell cycle-dependent
mechanisms, though the precise mechanisms by which
these compounds act to alter the process of erythroid
maturation and F cell production remain a point of con-
tinued investigation. It should be stressed that not all
cytotoxic chemotherapeutic agents can induce the synth-
esis of HbF, indicating some degree of specificity in the
signaling pathway requirements for g-globin induction.
Further, while cell cycle delay can contribute to induction
of g-globin transcription, other events, for example, altera-
tions in chromatin structure, are likely required for full
activation of g gene expression. Even in the compounds
identified here, which were selected for a relative lack of in
vitro toxicity, a significant (P < 0:01) trend between max-
imal g induction and onset of cytotoxicity can be observed.
The apparent outlier, PHA, may be explained by the
relatively long period of time (96 hr) required for max-
imal g transcription and the shorter time periods used for
stress gene measurement (<25 hr). An onset of cytotoxicity
was frequently observed at concentrations close or at that
required for maximal g-globin induction, producing steep,
bell-shaped dose–response curves (e.g. Fig. 4), strongly
suggesting cell stress mechanisms form an obligate part of
g-globin-inducing action.
Here, we have developed screening methods useful in
identifying compounds which stimulate g-globin transcrip-
tion and promote HbF production. The novel chemical
compounds identified here provide pharmacophores for the
development of new HbF elevating compounds for treat-
ment of sickle disease and possibly Cooley’s anemia. They
further provide tools by which the multiple mechanisms of
pharmacological up-regulation of g-globin transcription
may be investigated.
2 J.D.H., unpublished results.
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